Competitive problems in the drug industry
Subtitle: hearings before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, Ninetieth Congress, first session ...
Contributors: United States. Congress. Senate. Select Committee on Small Business. Committee on Monopoly.
Publisher: U.S. Govt. Print. Off.
Published: 1967
Place of publication: Washington
Language: eng
Subjects: Pharmaceutical industry -- United States.; Drugs -- Latin America.; Drugs -- marketing.; Competition, Unfair.; Oral medication.; Obesity -- United States.; Propoxyphene napsylate.
Other titles: Drug quality, competition, and government procurement of drugs.; Safety, efficacy, and usefulness of Darvon and other prparations containing propoxyphene.
Notes: Hearings held May 15, 1967-

Pts. 1-32 of these hearings held before the subcommittee under its earlier name: Subcommittee on Monopoly.

Oral hypoglycemic drugs.

Includes bibliographical references.
Table of contents: title: pt. 28. Oral hypoglycemic drugs.; title: pt. 29. Government procurement (vol. 8), (Bioequivalence and bioavailability).; title: v. 30.Pharmaceutical industry and medical education (vol. 1).; title: pt. 31. Safety and efficacy of anti-obesity drugs.; title: pt. 32. Pharmaceutical company practices in labeling and promoting prescription drugs sold in Latin America.; title: pt. 33 Drug quality, competition, and government procurement of drugs.; title: Pt. 34. Hearings before the Select Committee on Small Business, Jan. 31, Feb. 1 and 5, 1979.